Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
26 hedge funds and large institutions have $123M invested in Kezar Life Sciences in 2018 Q2 according to their latest regulatory filings, with 26 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
4.23% more ownership
Funds ownership: 0% → 4.23% (+4.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$27.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$26.2M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$22.2M |
| 4 |
CI
Cowen Inc
New York
|
+$18.4M |
| 5 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
+$12.1M |
Top Sellers
KZR Hedge Fund Activity: Q2 2018 in Review
26 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q2 2018, worth a combined $123M.
Buyers outnumbered sellers: 26 funds opened new KZR positions and 0 closed out — a net gain of 26 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $27.4M.
- 26 institutional investors held Kezar Life Sciences (KZR) as of Q2 2018, up from 0 in Q1 2018.
- Funds reported $123M of Kezar Life Sciences stock for Q2 2018.
- 26 funds opened new Kezar Life Sciences positions in Q2 2018 and 0 closed out, a net change of +26 holders.
- The largest Kezar Life Sciences buyer in Q2 2018 was Cormorant Asset Management, an estimated $27.4M added.
Based on aggregated 13F filings for Q2 2018.